Revisiting Chemo in EGFR-Mutant NSCLC

]]>(MedPage Today) -- Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to two randomized trials.A phase III trial from India showed...